NASDAQ · GOVXW
Healthcare · Biotechnology
$0.00
Down-$0.00 (-23.91%)
Updated Aug 23, 2026, 4:05 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
GOVXW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning GOVXW.
GOVXW research
Company profile and research snapshot.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · Nov 26, 2024
GeoVax Labs, a biotechnology company, announced that its CEO will present at the NobleCon20 conference. The company is developing COVID-19 vaccines and cancer immunotherapies, with its lead clinical programs being GEO-CM04S1 and Gedeptin.
GlobeNewswire Inc. · Nov 12, 2024
GeoVax Labs announced progress in its COVID-19 vaccine trials, including the BARDA/Project NextGen Phase 2b trial and upcoming data readouts from existing Phase 2 trials. The company also provided updates on its Gedeptin and GEO-MVA Mpox vaccine programs.
GlobeNewswire Inc. · Nov 5, 2024
GeoVax, a biotechnology company, will report its third quarter 2024 financial results and provide a corporate update on November 12, 2024. The company will host a conference call and webcast to discuss the results and provide an update on its clinical programs.
GlobeNewswire Inc. · Oct 2, 2024
GeoVax Labs, a biotechnology company, announced that its Chairman & CEO, David Dodd, will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GOVXW.
No results
No recent SID articles mention GOVXW.
